Bristol Myers Squibb Shares Update On Phase 3 CheckMate -73L Trial; Says Trial Did Not Meet Its Primary Endpoint Of Progression-Free Survival In Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer
Bristol Myers Squibb Shares Update On Phase 3 CheckMate -73L Trial; Says Trial Did Not Meet Its Primary Endpoint Of Progression-Free Survival In Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer
Bristol Myers Squibb (NYSE:BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated Opdivo (nivolumab) with concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoy (ipilimumab) versus CCRT followed by durvalumab in patients with unresectable stage III NSCLC. The observed adverse events of Opdivo with CCRT followed by Opdivo plus Yervoy were generally consistent with the known profiles of each component in the regimen.
百时美施贵宝（纽约证券交易所代码：BMY）今天宣布，在不可切除的局部晚期III期非小细胞肺癌（NSCLC）中，3期CheckMate-73L试验未达到其无进展存活率（PFS）的主要终点。CheckMate -73L 已评估 Opdivo （nivolumab）同时进行放化疗（CCRT），其次是 Opdivo 加 耶尔沃伊 （ipilimumab）对比CCRT，其次是杜伐单抗，用于不可切除的III期非小细胞肺癌患者。观察到的不良事件 Opdivo 其次是 CCRT Opdivo 加 耶尔沃伊 总体上与该方案中每种成分的已知特征一致。
"Unfortunately, adding immunotherapy concurrently with definitive chemoradiation did not improve PFS outcomes in this setting," said Joseph Fiore, vice president, global program lead, thoracic cancers, Bristol Myers Squibb. "There remains a critical need to improve long-term outcomes for these patients and we believe these results will help inform future drug development efforts in this setting. We want to thank the patients, families and investigators for their contributions to this important research."
百时美施贵宝副总裁兼胸癌全球项目负责人约瑟夫·菲奥雷说：“不幸的是，在这种环境下，在进行明确的放化疗的同时添加免疫疗法并不能改善PFS的预后。”“仍然迫切需要改善这些患者的长期疗效，我们相信这些结果将有助于为未来的药物研发工作提供信息。我们要感谢患者、家属和研究人员对这项重要研究的贡献。”
The company will complete a full evaluation of the data and work with investigators to share the results with the scientific community.
该公司将完成对数据的全面评估，并与研究人员合作，与科学界分享结果。
Opdivo and Opdivo-based combinations have shown positive outcomes and are approved treatment options for eligible patients with resectable or metastatic NSCLC.
Opdivo 和 Opdivo-基于药物的组合已显示出积极的疗效，是符合条件的可切除或转移性非小细胞肺癌患者的批准治疗选择。
译文内容由第三方软件翻译。